Home
About
- Our Team
- Careers
News
Contact

Technology
Diagnostics
Therapeutics
- Drug Discovery
- Safer Drugs
Products
- Sales
- Licensing & Distribution
Services
Resources

AmberGen awarded Phase I SBIR grant for the application of photocleavable bead technology to glycomics

September 2012/in News /by Kenneth Rothschild

Share this entry

https://www.ambergen.com/wp-content/uploads/logo-retina.png 0 0 Kenneth Rothschild https://www.ambergen.com/wp-content/uploads/logo-retina.png Kenneth Rothschild2012-09-27 13:44:382016-11-10 12:44:45AmberGen awarded Phase I SBIR grant for the application of photocleavable bead technology to glycomics

Menu

Home
About
Technology
Diagnostics
Therapeutics

Products
Services
Resources
News
Contact

Get in Touch

AmberGen, Inc.

313 Pleasant St.

Watertown, MA 02472

(617) 932-9990

info@ambergen.com

Recent News

Recent Posts

AmberGen receives US Patent 9,910,034 increasing its broad coverage on PC-PURE™ photo-affinity biomarker purification and enrichment technology for improving the accuracy of diagnostic testing March 2018
Paper published in PLOS ONE in collaboration with Boston Children’s Hospital “Photocleavage-based affinity purification of biomarkers from serum: Application to multiplex allergy testing” describing application of AmberGen’s PC-PURE™ to highly multiplex in vitro allergy testing (AllerBead™) February 2018

© 2019 - AmberGen Inc. Website designed in Massachusetts

AmberGen receives US Patent 8,148,062 for detecting disease causing genetic... AmberGen receives US Patent 8,278,045 for detecting chain truncation mutations...

Scroll to top